The effect of nebulized N-acetylcysteine on the phlegm of chronic obstructive pulmonary disease: the NEWEST study.

Humans Acetylcysteine / administration & dosage Pulmonary Disease, Chronic Obstructive / drug therapy Male Female Aged Prospective Studies Nebulizers and Vaporizers Middle Aged Forced Expiratory Volume / drug effects Administration, Inhalation Vital Capacity / drug effects Expectorants / administration & dosage Treatment Outcome
Chronic bronchitis Chronic obstructive pulmonary disease N-acetylcysteine Nebulizer

Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 31 12 2023
accepted: 22 08 2024
medline: 3 9 2024
pubmed: 3 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

Phlegm is prevalent symptom in patients with chronic obstructive pulmonary disease (COPD). Few studies have investigated the effectiveness of N-acetylcysteine (NAC) nebulizer therapy in COPD patients. We evaluated the effect of nebulized NAC on the improvement of phlegm symptom in COPD patients. This was a 12-week, prospective, single-arm, open-label, phase IV multi-center trial (NCT05102305, Registration Date: 20-October-2021). We enrolled patients aged ≥ 40 years with post bronchodilator forced expiratory volume in one second/forced vital capacity (FEV In total, 100 COPD patients were enrolled from 10 hospitals. The mean age of the patients was 71.42 ± 8.20 years, with 19.78% being current-smokers and 80.22% being ex-smokers. The mean smoking pack-years was 40.32 ± 35.18. The mean FVC, FEV In this study, we have established the effectiveness and safety of nebulized NAC over 12 weeks.

Sections du résumé

BACKGROUND BACKGROUND
Phlegm is prevalent symptom in patients with chronic obstructive pulmonary disease (COPD). Few studies have investigated the effectiveness of N-acetylcysteine (NAC) nebulizer therapy in COPD patients. We evaluated the effect of nebulized NAC on the improvement of phlegm symptom in COPD patients.
METHODS METHODS
This was a 12-week, prospective, single-arm, open-label, phase IV multi-center trial (NCT05102305, Registration Date: 20-October-2021). We enrolled patients aged ≥ 40 years with post bronchodilator forced expiratory volume in one second/forced vital capacity (FEV
RESULTS RESULTS
In total, 100 COPD patients were enrolled from 10 hospitals. The mean age of the patients was 71.42 ± 8.20 years, with 19.78% being current-smokers and 80.22% being ex-smokers. The mean smoking pack-years was 40.32 ± 35.18. The mean FVC, FEV
CONCLUSION CONCLUSIONS
In this study, we have established the effectiveness and safety of nebulized NAC over 12 weeks.

Identifiants

DOI: 10.1186/s12890-024-03243-y PMID: 39223526
pubmed: 39223526
doi: 10.1186/s12890-024-03243-y
pii: 10.1186/s12890-024-03243-y
doi:

Substances chimiques

Acetylcysteine WYQ7N0BPYC
Expectorants 0

Types de publication

Journal Article Multicenter Study Clinical Trial, Phase IV

Langues

eng

Sous-ensembles de citation

IM

Pagination

434

Informations de copyright

© 2024. The Author(s).

Références

Sin DD. Chronic obstructive pulmonary disease and the airway microbiome: what respirologists need to know. Tuberc Respir Dis. 2023;86(3):166–75.
doi: 10.4046/trd.2023.0015
Jo YS. Long-term outcome of chronic obstructive pulmonary disease: a review. Tuberc Respir Dis. 2022;85(4):289–301.
doi: 10.4046/trd.2022.0074
Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG, et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med. 2017;377(10):911–22.
doi: 10.1056/NEJMoa1701632 pubmed: 28877023 pmcid: 5706541
Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–21.
doi: 10.1016/S0140-6736(04)16900-6 pubmed: 15325838
Kim WD. Phenotype of chronic obstructive pulmonary disease based on computed tomography-defined underlying pathology. Tuberc Respir Dis. 2022;85(4):302–12.
doi: 10.4046/trd.2022.0029
Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care. 2007;52(9):1134–46; discussion 1146-1139.
pubmed: 17716382
Lo Bello F, Ieni A, Hansbro PM, Ruggeri P, Di Stefano A, Nucera F, Coppolino I, Monaco F, Tuccari G, Adcock IM, et al. Role of the mucins in pathogenesis of COPD: implications for therapy. Expert Rev Respir Med. 2020;14(5):465–83.
doi: 10.1080/17476348.2020.1739525 pubmed: 32133884
Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–94.
doi: 10.1016/S2213-2600(13)70286-8 pubmed: 24621680
Tang W, Zhu D, Wu F, Xu JF, Yang JP, Deng ZP, Chen XB, Papi A, Qu JM. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. Eur Rev Med Pharmacol Sci. 2023;27(11):5119–27.
pubmed: 37318485
Kim V, Criner GJ. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. Curr Opin Pulm Med. 2015;21(2):133–41.
doi: 10.1097/MCP.0000000000000145 pubmed: 25575367 pmcid: 4373868
Choi JY, Yoon HK, Park SJ, Park YB, Shin KC, Na JO, Yoo KH, Jung KS, Kim YK, Rhee CK. Chronic bronchitis is an independently associated factor for more symptom and high-risk groups. Int J Chron Obstruct Pulmon Dis. 2016;11:1335–41.
pubmed: 27382269 pmcid: 4922782
Alghamdi SM, Alsulayyim AS, Alasmari AM, Philip KEJ, Buttery SC, Banya WAS, et al. Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial. Thorax. 2023;78(2):136–43.
doi: 10.1136/thorax-2022-219077 pubmed: 35948418
Bennett WD, Henderson AG, Ceppe A, Zeman KL, Wu J, Gladman C, Fuller F, Gazda S, Button B, Boucher RC, et al. Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis. ERJ Open Res. 2020;6(3):00269–2020.
doi: 10.1183/23120541.00269-2020 pubmed: 32802823 pmcid: 7418818
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Gabriella Matera M. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–61.
doi: 10.1183/16000617.00002215 pubmed: 26324807 pmcid: 9487680
Hirsch SR, Kory RC. An evaluation of the effect of nebulized N-acetylcysteine on sputum consistency. J Allergy. 1967;39(5):265–73.
doi: 10.1016/0021-8707(67)90090-1 pubmed: 5337455
Gallon AM. Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Thorax. 1996;51(4):429–32.
doi: 10.1136/thx.51.4.429 pubmed: 8733499 pmcid: 1090682
Lim JU, Lee J-H, Kim T-H, Lee JS, Lee S-D, Oh Y-M, Rhee CK. Alternative definitions of chronic bronchitis and their correlation with CT parameters. Int J Chron Obstruct Pulmon Dis. 2018;13:1893–9.
doi: 10.2147/COPD.S164055 pubmed: 29942122 pmcid: 6005312
Choi JY, Yoon HK, Lee SY, Kim JW, Choi HS, Kim YI, Jung KS, Yoo KH, Kim WJ, Rhee CK. Comparison of clinical characteristics between chronic bronchitis and non-chronic bronchitis in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2022;22(1):69.
doi: 10.1186/s12890-022-01854-x pubmed: 35184738 pmcid: 8858532
Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD. Sci Rep. 2023;13(1):8183.
doi: 10.1038/s41598-023-35223-3 pubmed: 37210420 pmcid: 10199945
Rhee CK, Chau NQ, Yunus F, Matsunaga K, Perng DW, on behalf the CAotA. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respirology. Respirology. 2019;24(10):1018–25.
doi: 10.1111/resp.13633 pubmed: 31276272
Caramori G, Ruggeri P, Arpinelli F, Salvi L, Girbino G. Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature. Int J Chron Obstruct Pulmon Dis. 2019;14:1085–97.
doi: 10.2147/COPD.S190215 pubmed: 31190791 pmcid: 6536120
Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103(4):542–51.
doi: 10.1016/j.rmed.2008.11.003 pubmed: 19138505
Caramori G, Ruggeri P, Casolari P, Chung KF, Girbino G, Adcock IM. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2017;11(12):955–67.
pubmed: 28956463
Lee EG, Rhee CK. The clinical efficacy of AG NPP709 (Synatura((R))) in patients with chronic bronchitis type stable chronic obstructive pulmonary disease. J Thorac Dis. 2020;12(5):2435–42.
doi: 10.21037/jtd.2020.03.61 pubmed: 32642149 pmcid: 7330415

Auteurs

Chin Kook Rhee (CK)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Seong Yong Lim (SY)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Won-Yeon Lee (WY)

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Yonsei University Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, South Korea.

Ji Ye Jung (JY)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Yong Bum Park (YB)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, South Korea.

Chang Youl Lee (CY)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, South Korea.

Yong Il Hwang (YI)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea.

Jin Woo Song (JW)

Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Won-Il Choi (WI)

Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.

Kwang Ha Yoo (KH)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine, 120 Neungdong-Ro, Gwangjin-Gu, Seoul, 05029, South Korea. khyou@kuh.ac.kr.

Ki Uk Kim (KU)

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea.

Yu-Il Kim (YI)

Division of Pulmonary Medicine, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, South Korea.

Tae-Hyung Kim (TH)

Division of Pulmonary and Critical Care Medicine. Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea.

Seong Ju Park (SJ)

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, South Korea.

Kyeong-Cheol Shin (KC)

Division of Pulmonology and Allergy, Department of Internal Medicine, Regional Center for Respiratory Disease, College of Medicine, Yeungnam University, Daegu, South Korea.

Soo-Jung Um (SJ)

Division of Respiratory Medicine, Department of Internal Medicine, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, South Korea.

Hyoung Kyu Yoon (HK)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Ho Sung Lee (HS)

Division of Respiratory Medicine, Soon Chun Hyang University Hospital Cheonan, Cheonan, South Korea.

Deog Kyeom Kim (DK)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.

Ah Young Leem (AY)

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés soufrés › Cystéine › Acétylcystéine › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Équipement et fournitures › Nébuliseurs et vaporisateurs › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Ventilation pulmonaire › Volume expiratoire maximal par seconde › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par inhalation › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiologiques respiratoires › Capacité pulmonaire totale › Capacité vitale › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents de l'appareil respiratoire › Expectorants › The effect of nebulized N-acetylcysteine on...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › The effect of nebulized N-acetylcysteine on...